Perrigo Co (Perrigo Co) Change In Working Capital : $-59 Mil (TTM As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Perrigo Co Change In Working Capital?

Perrigo Co's change in working capital for the quarter that ended in Dec. 2023 was $129 Mil.

Perrigo Co's change in working capital for the fiscal year that ended in Dec. 2023 was $-59 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Perrigo Co Change In Working Capital Historical Data

The historical data trend for Perrigo Co's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perrigo Co Change In Working Capital Chart

Perrigo Co Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-313.50

-69.20

-295.40

20.00

-58.50

Perrigo Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															118.10	-87.90	-78.70	-21.10	129.20

Perrigo Co Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Perrigo Co Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Perrigo Co's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Perrigo Co (Perrigo Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perrigo Co PLC (NYSE:PRGO) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

PIG:Germany

Address

The Sharp Building, Hogan Place, Dublin, IRL, D02 TY74

Website

https://www.perrigo.com

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Executives

Robert Willis	officer: Acting CHRO	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Alison Ives	officer: EVP & Chief Scientific Officer	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Eduardo Guarita Bezerra	officer: EVP & Chief Financial Officer	C/O FRESH DEL MONTE PRODUCE INC., PO BOX 149222, CORAL GABLES FL 33134
Patrick Lockwood-taylor	director, officer: CEO	C/O PERRIGO COMPANY PLC, 430 MONROE AVE NW, GRAND RAPIDS MI 49503
Julia M Brown	director	C/O ABLE BRANDS CO., 30 HUDSON YARDS, NEW YORK NY 10001
Triona Schmelter	officer: EVP & President CSCA	2021 SPRING ROAD, SUITE 600, OAK BROOK IL 60523
Geoffrey M. Parker	director	15 RIORDAN PLACE, MENLO PARK CA 94025
Svend Andersen	director	C/O PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Murray S Kessler	director, officer: CEO	714 GREEN VALLEY ROAD, GREENSBORO NC 27408
Thomas Farrington	officer: Senior VP and CIO	4012 W. CANTERBURY CT., NEQUON WI 53092
Dillard James E Iii	officer: EVP, Chief Scientific Officer	6601 WEST BROAD STREET, RICHMOND VA 23230
Ronald Craig Janish	officer: EVP, Global Op. & Supply Chain	PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Grainne Quinn	officer: EVP, Chief Medical Officer	PERRIGO COMPANY PLC, 515 EASTERN AVENUE, ALLEGAN MI 49010
Albert Manzone	director	C/O MERISANT, AVENUE JEAN-JACQUES ROUSSEAU 7, NEUCHATEL V8 CH-2000
Kyle Hanson	officer: EVP & General Counsel